Company Filing History:
Years Active: 2017
Title: Innovations of David Allsop: Pioneering Research in Alzheimer's Disease
Introduction: David Allsop, an accomplished inventor based in Carnforth, GB, has made significant strides in the realm of medical innovation. With a focus on neurodegenerative diseases, specifically Alzheimer's, he has developed a patent that holds promise for prevention and treatment.
Latest Patents: Allsop's patent titled "Compositions for binding to amyloid proteins" is aimed at addressing the challenges posed by Alzheimer's disease. This innovative composition includes carrier particles that are linked to peptide constructs. These constructs contain a peptide binding sequence, which is capable of interacting with amyloid proteins, and a transit amino acid sequence. Notably, the binding sequence may take the form of a retroinverted D-peptide mimetic of an L-peptide binding sequence, while the transit sequence can be a D-peptide mimetic of an L-peptide transit sequence, such as TAT. The preferred peptide construct utilized in his patent features the sequence rGffvlkGrrrrqrrkkrGy, and liposomes serve as the preferred carrier particles.
Career Highlights: David Allsop's work is closely associated with Lancaster University Business Enterprises Limited, where he applies his expertise in the intersection of science and commercial application. His insights have proved invaluable in the pursuit of tangible solutions to pressing medical challenges.
Collaborations: A key figure in Allsop's professional journey is Mark Neville Taylor, who has collaborated with him on various projects. Their combined efforts reflect a shared commitment to advancing research in neurodegenerative diseases and developing innovative treatments.
Conclusion: David Allsop stands out as an influential inventor in the field of medical innovation. His patent for compositions binding to amyloid proteins not only highlights his dedication to addressing Alzheimer's disease but also represents a significant advancement in understanding and potentially mitigating its effects. The collaboration with Mark Neville Taylor further enriches his contributions to the field, promising a brighter future for those affected by this challenging condition.